spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  hypervolemic hyponatremia 

 HSMN NewsFeed - 2 Dec 2019
Cumberland Pharmaceuticals Receives FDA Approval for RediTrex(TM) Product Line
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Sep 2018
Cumberland Pharmaceuticals Announces Senior Music Industry Executive Joins Its Board Of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Aug 2018
Cumberland Pharmaceuticals Appoints New Senior Executive
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Apr 2018
Cumberland Pharmaceuticals Expands into Oncology Support
Biopharmaceuticals Oncology Licensing Distribution
 HSMN NewsFeed - 25 Sep 2017
Cumberland Pharmaceuticals Launches Promotion of Totect(R) in The U.S. for Emergency Oncology Intervention
Biopharmaceuticals Oncology Product Launch
 HSMN NewsFeed - 25 Jan 2016
Piramal Critical Care and Cumberland Pharmaceuticals Announce Launch of Caldolor and Vaprisol Co-Promotion
Biopharmaceuticals Distribution Product Launch
 HSMN NewsFeed - 21 May 2009
FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Apr 2009
Astellas Launches Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
Biopharmaceuticals
 HSMN NewsFeed - 22 Oct 2008
FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Dec 2007
New Drug Application for Tolvaptan, Otsuka's Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 25 Oct 2007
Study Shows VAPRISOL(R) is Effective in Increasing Serum Sodium Levels and Well-Tolerated in Patients With Euvolemic or Hypervolemic Hyponatremia
Biopharmaceuticals
 HSMN NewsFeed - 10 Oct 2007
Data Show Vaprisol(R) Is Effective & Safe in Promptly Increasing Serum Sodium Levels in Patients With Euvolemic or Hypervolemic Hyponatremia
Biopharmaceuticals
 HSMN NewsFeed - 20 Sep 2007
Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
Biopharmaceuticals
 HSMN NewsFeed - 2 Mar 2007
FDA Approves Astellas' Vaprisol(R) for the Treatment of Hypervolemic Hyponatremia
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Nov 2006
New Data on Otsuka's Investigational Product for Hyponatremia Presented at American Heart Association Annual Meeting
Biopharmaceuticals Cardiology
Return to NewsFeed  

 Additional items found! 2

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 2 additional stories matching:
hypervolemic hyponatremia
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!